For 20 years botulinum toxin A has been used for the treatment of a variety of disorders characterised by pathologically increased muscle contraction. Recently, treatment of tension headache, migraine, cluster headache, and myofascial pain syndromes of neck, shoulder girdle, and back with botulinum toxin A has become a rapidly expanding new field of research. Several modes of action are discussed for these indications. The blockade of cholinergic innervation reduces muscular hyperactivity for 3 to 6 months. Degenerative changes in the musculoskeletal system of the head and neck are prevented. Nociceptive afferences and blood vessels of the pericranial muscles are decompressed and muscular trigger points and tender points are resolved. The normalisation of muscle spindle activity leads to a normalisation of muscle tone and central control mechanisms of muscle activity. Oromandibular dysfunction is eliminated and muscular stress removed. However, the effect of botulinum toxin A cannot be explained by muscular actions only. Its retrograde uptake into the central nervous system modulates the expression of substance P and enkephalins in the spinal cord and nucleus raphe. Recent findings suggest an inhibition of sterile inflammation which may lead to a blockade of the neurogenic inflammation believed to be the pathophysiological substrate of primary headache disorders. The efficacy of botulinum toxin A in the treatment of pain disorders is being investigated in several studies at the moment. The results and experiences obtained so far present new alternatives in the treatment of chronic pain disorders. The practical use of botulinum toxin A is demonstrated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s001150050749 | DOI Listing |
Tech Coloproctol
January 2025
Royal Glamorgan Hospital, Llantrisant, Wales, UK.
Background: Anal fissure is one of the most painful anal conditions. Various management options are available, including topical nitrites, calcium channel blockers, botulinum toxin injection, and lateral internal sphincterotomy. This study aimed to assess the efficacy and safety of botulinum toxin A (BT) injection for the management of symptomatic chronic anal fissures by conducting a systematic review of the literature and meta-analysis of published randomized controlled trials (RCTs).
View Article and Find Full Text PDFRehabilitacion (Madr)
January 2025
University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey.
Objective: Spasticity developing in the upper extremity in stroke patients causes disability by limiting movement and causing pain. This study investigates the effects of botulinum toxin injections on pain, functionality, spasticity, and range of motion in hemiplegic patients with post-stroke spasticity.
Materials And Methods: The study involved a double-blind, prospective, randomized controlled trial with thirty-one stroke patients aged 35-80 who developed upper extremity spasticity.
Clin Park Relat Disord
June 2024
New York Medical College, Valhalla, NY, USA.
Background: Lower extremity dystonia (LED) is a frequent complication of Parkinson disease (PD). Treatment with botulinum neurotoxinA (BoNTA) over 8 years was retrospectively reviewed.Cases14 patients with LED received an average of 3.
View Article and Find Full Text PDFClin Case Rep
January 2025
Toxicological Research Center, Excellence Center & Department of Clinical Toxicology, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.
Botulism symptoms after cosmetic botulinum toxin-A (BTX-A) injections happen very rarely, and it needs careful attention since it can be life-threatening. Hence, it is advised to meticulously check the technique, dose, and authenticity of the BTX-A before injections to reduce the adverse effects.
View Article and Find Full Text PDFCureus
December 2024
General Dentistry, College of Dentistry, King Saud bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Excessive gingival display (EGD), commonly known as a gummy smile (GS), is a cosmetic concern that involves exposing a significant area of gum tissue during a smile, rendering it unaesthetic. Gingival exposure greater than 3 mm is deemed aesthetically displeasing and often necessitates treatment to mask the gummy smile. The causes of EGD are multifactorial, including altered passive eruption (APE), hypermobile upper lip (HUL), short lip length, increased vertical maxillary component, gingival hyperplasia, dentoalveolar extrusion, and more.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!